EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq futures fall as oil prices jump, key earnings loom
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
| (NASDAQ: EYPT) | Delayed: 0.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.44 | 52 Week High | $ | |||
| Open | $0.44 | 52 Week Low | $ | |||
| Day High | $0.44 | P/E | N/A | |||
| Day Low | $0.44 | EPS | $ | |||
| Volume | 989,106 | |||||
